Promoted Content
Promoted Content

Find Ophthalmology Drugs in Phase III Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Travoprost

            Therapeutic Area: Ophthalmology Product Name: iDose TR

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2021

            Details:

            iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Phentolamine

            Therapeutic Area: Ophthalmology Product Name: Nyxol

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2021

            Details:

            The current study builds on the positive results achieved in Ocuphire's recent Phase 2b MIRA-1 trial, which provided evidence of Nyxol’s ability to more rapidly return pupil diameter back to normal baselines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tropicamide,Phenylephrine Hydrochloride

            Therapeutic Area: Ophthalmology Product Name: MydCombi

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 29, 2020

            Details:

            The NDA submission follows the initial enrollment of the VISION-1 study, Eyenovia’s Phase 3 study for MicroLine in presbyopia, with top-line data expected the first half of 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Varenicline Tartrate

            Therapeutic Area: Ophthalmology Product Name: OC-01

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 18, 2020

            Details:

            The NDA submission for OC-01, is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Phentolamine

            Therapeutic Area: Ophthalmology Product Name: Nyxol

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oculos Development Services

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            Nyxol, a stable eye drop formulation of phentolamine mesylate, has been shown to reverse mydriasis in a recently completed Phase 2b clinical trial (MIRA-1). MIRA-2 trials are to evaluate the efficacy and safety of Nyxol vs commonly used mydriatic (dilating) drops.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Phentolamine

            Therapeutic Area: Ophthalmology Product Name: Nyxol

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $1.7 million Upfront Cash: Undisclosed

            Deal Type: Funding November 16, 2020

            Details:

            Ocuphire Pharma received grant from the National Eye Institute (NEI) to continue studies on APX3330, as well as second generation compounds, APX2009 and APX2014. It also received Japanese Patent for daily ophthalmic use of nyxol to Improve Visual Performance.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tanfanercept

            Therapeutic Area: Ophthalmology Product Name: HBM9036

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in China.